Rare and Atypical Diabetes Network

Launched by UNIVERSITY OF SOUTH FLORIDA · Sep 14, 2022

Keywords

ClinConnect Summary

The RADIANT clinical trial is studying rare and unusual forms of diabetes to better understand their causes and how they affect people. The goal is to identify individuals and families who have these atypical types of diabetes, which may include cases where diabetes develops at a young age, is linked to other health issues, or has unique characteristics like very low insulin needs or rapid changes in blood sugar levels. By gathering information and samples from participants, researchers hope to uncover new insights into these conditions.

To be part of the trial, participants should have specific features that suggest they might have an atypical form of diabetes, such as being diagnosed with Type 2 diabetes at a very young age or having certain genetic patterns. The study is open to people of all ages and genders, but some individuals with more common types of diabetes will not be eligible. Participants will undergo tests and evaluations to help researchers learn more about their condition. This trial is an important step towards improving the understanding and treatment of rare diabetes forms, which can help those affected receive better care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The following criteria or phenotypes will be considered for suspecting "atypical" participants:
• • Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
• • Mendelian pattern, especially with early onset (\<18 years old)
• • Syndromic (multiple systems involved)
• • Lipodystrophic
• • Extremes of BMI
• • "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
• • Non-progressive
• • Rapidly progressive ("fulminant")
• • Low insulin requirements (\<0.5 u/kg/day)
• • Cyclical hyperglycemia with periods of remission
• • Lean persons with polycystic ovarian syndrome (PCOS)
• • History of gestational diabetes (GDM) when lean
• • Lean insulin-resistant persons
• * If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
• • oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)
• Exclusion Criteria:
• • Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
• • Refusal of consent for genetic testing
• • Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
• • Women who are currently pregnant